Rosen Comments on Prospects for COVID-19 Vaccine This Year
July 30, 2020
Memphis Business Journal
Partner David Rosen was quoted in a Memphis Business Journal article, “A COVID-19 vaccine this year? It’s a long shot, but it’s possible,” about drug companies considering the use of a little-known regulatory tool to push their COVID-19 vaccines into Americans’ hands before the end of the year.
Rosen, who chairs the firm’s FDA regulatory practice, said the government’s decision to enact the Public Readiness and Emergency Preparedness (PREP) Act in response to the COVID-19 outbreak limits the legal repercussions that drugmakers could face if their COVID-19 products cause physical injury, death and other ill effects to users.
(Subscription required.)
People
Related News
August 19, 2025
In the News
Gustavo Resendiz Featured in Q&A on Secondary Market Momentum – 'Investors want liquidity'
Foley & Lardner LLP partner Gustavo Resendiz is featured in the Crunchbase News Q&A, "Why Secondary Funds Still Can’t Keep Up With Investor Demand," lending insight into the accelerating investor momentum towards secondary transactions.
August 18, 2025
In the News
David Simon Coauthors Piece on Empowering Lawyers as Strategic Business Partners
Foley & Lardner LLP partner David Simon coauthored The Agenda article, "Turn Your Corporate Lawyer into a Strategic Weapon," published by Financial Times.
August 15, 2025
In the News
Gregory Husisian on Voluntary Disclosures to Customs – 'Importing has never been riskier'
Foley & Lardner LLP partner Gregory Husisian authored the SupplyChainBrain article, "Best Practices for Making Voluntary Disclosures to Customs," sharing insight on this vital strategy for companies looking to mitigate risk from U.S. Customs and Border Protection.